Key result
Ezetimibe mimics Danuglipron binding to the GLP-1 receptor in computational modeling.
Computational molecular docking suggests that the antihyperlipidemic drug ezetimibe may possess GLP-1 receptor agonist potential.
Drug repositioning has recently become a crucial tool for discovering new biological effects of clinically used drugs. This study investigated the GLP-1 receptor agonist activity of antihyperlipidemic drugs, which are widely used by diabetic patients and those with cardiovascular diseases.The study was conducted using CB-Dock, an internet-based m olecular docking program. The binding energies (kcal/mol) of the selected antihyperlipidemic drugs to the GLP-1 receptor were calculated, and Danuglipron was used as a reference compound. A comparison of the binding energies revealed that both the binding energy and localization of Ezetimibe were quite like those of Danuglipron. Following this analysis, the physicochemical and toxicological properties of Ezetimibe, the most potent compound, and Danuglipron were compared computationally.
No takes yet. Share an insight, caveat, or question.
Buran et al. (2026) studied this question. Ezetimibe (antihyperlipidemic drugs) vs. Danuglipron was evaluated on Binding energies (kcal/mol) to the GLP-1 receptor and localization. In silico molecular docking revealed that the binding energy and localization of Ezetimibe to the GLP-1 receptor were highly similar to the reference compound Danuglipron.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: